U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940
|_| Check this box if no longer subject to Section 16. Form 4 or Form 5
obligations may continue. See Instruction 1(b).
================================================================================
1. Name and Address of Reporting Person*
Rosenwald, M.D., Lindsay A.
--------------------------------------------------------------------------------
(Last) (First) (Middle)
c/o Paramount Capital Asset Management, Inc., 787 Seventh Avenue, 48th Floor
--------------------------------------------------------------------------------
(Street)
New York NY 10019
--------------------------------------------------------------------------------
(City) (State) (Zip)
================================================================================
2. Issuer Name and Ticker or Trading Symbol
Cell Therapeutics, Inc. (CTIC)
================================================================================
3. IRS Identification Number of Reporting Person, if an Entity (Voluntary)
================================================================================
4. Statement for Month/Year
September 2000
================================================================================
5. If Amendment, Date of Original (Month/Year)
================================================================================
6. Relationship of Reporting Person to Issuer
(Check all applicable)
|_| Director |X| 10% Owner
|_| Officer (give title below) |_| Other (specify below)
================================================================================
7. Individual or Joint/Group Filing (Check Applicable Line)
|_| Form filed by one Reporting Person
|X| Form filed by more than one Reporting Person
================================================================================
* If the Form is filed by more than one Reporting Person, see Instruction
4(b)(v).
<PAGE>
================================================================================
Table I -- Non-Derivative Securities Acquired, Disposed of,
or Beneficially Owned
================================================================================
<TABLE>
<CAPTION>
6.
4. 5. Owner-
Securities Acquired (A) or Amount of ship
3. Disposed of (D) Securities Form: 7.
Transaction (Instr. 3, 4 and 5) Beneficially Direct Nature of
2. Code ---------------------------- Owned at End (D) or Indirect
1. Transaction (Instr. 8) (A) of Month Indirect Beneficial
Title of Security Date ------------ Amount or Price (Instr. 3 (I) Ownership
(Instr. 3) (mm/dd/yy) Code V (D) and 4) (Instr.4) (Instr. 4)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Common Stock 09/11/00 P 5,946 A $41.188 4,973,087(1) I By The Aries Master
Fund II(2)
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 09/11/00 P 3,097 A $41.188 4,973,087(1) I By Aries Domestic
Fund, L.P.(2)
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 09/11/00 P 957 A $41.188 4,973,087(1) I By Aries Domestic
Fund II, L.P.(2)
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 09/29/00 J 1,460,877(3) A $.001 4,973,087(1) D
====================================================================================================================================
</TABLE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
Page 1 of 3
<PAGE>
FORM 4 (continued)
Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
================================================================================
<TABLE>
<CAPTION>
9. 10.
Number Owner-
of ship
2. Deriv- Form of
Conver- 5. 7. ative Deriv- 11.
sion Number of Title and Amount Secur- ative Nature
of Derivative 6. of Underlying 8. ities Secur- of
Exer- 4. Securities Date Securities Price Bene- ity: In-
cise 3. Trans- Acquired (A) Exercisable and (Instr. 3 and 4) of ficially Direct direct
Price Trans- action or Disposed Expiration Date ---------------- Deriv- Owned (D) or Bene-
1. of action Code of(D) (Month/Day/Year) Amount ative at End In- ficial
Title of Deriv- Date (Instr. (Instr. 3, ---------------- or Secur- of direct Owner-
Derivative ative (Month/ 8) 4 and 5) Date Expira- Number ity Month (I) ship
Security Secur- Day/ ------ ------------ Exer- tion of (Instr. (Instr. (Instr. (Instr.
(Instr. 3) ity Year) Code V (A) (D) cisable Date Title Shares 5) 4) 4) 4)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
N/A
====================================================================================================================================
</TABLE>
Explanation of Responses:
(1) See Attachment A.
(2) Paramount Capital Asset Management, Inc. ("PCAM") is the general partner
of each of the Aries Domestic Fund, L.P. ("Aries I") and Aries Domestic
Fund II, L.P. ("Aries II"), each a Delaware limited partnership, and also
serves as the investment manager of the Aries Master Fund II, a Cayman
Island exempted company (the "Master Fund"), which also owns securities of
the Issuer. Dr. Rosenwald is the chairman and sole stockholder of PCAM. As
a result, Dr. Rosenwald and PCAM may be deemed to have voting and
investment control over the securities of the issuer owned by the Aries
Funds under Rule 16a-(a)(1) of the Securities Exchange Act of 1934. Dr.
Rosenwald and PCAM disclaim beneficial ownership of the securities held by
the Aries Funds, except to the extent of its pecuniary interest therein,
if any.
(3) Dr. Rosenwald acquired these shares as a milestone payment by the Company
to the former shareholders of PolaRx Biopharmaceuticals, Inc. Shareholder
approval for this issuance was obtained on September 29, 2000. Details
regarding the foregoing are described in the Definitive Proxy Statement
filed by the Company on September 11, 2000.
** Intentional misstatements or omissions of facts constitute Federal Criminal
Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
/s/ Lindsay A. Rosenwald, M.D. October 6, 2000
--------------------------------------------- -----------------------
** Signature of Reporting Person Date
Lindsay A. Rosenwald, M.D.
Note: File three copies of this Form, one of which must be manually signed. If
space provided is insufficient, see Instruction 6 for procedure.
Page 2 of 3
<PAGE>
Attachment A
Securities beneficially owned by Dr. Rosenwald are presented on an as-converted
basis and consist of the following:
1. 2,434,795 shares of Common Stock owned directly by Dr. Rosenwald;
2. 780,578 shares of Common Stock issuable upon conversion of 1,688 shares of
Series C Convertible Preferred Stock; Warrants to purchase 257,219 shares
of Common Stock; and 644,264 shares of Common Stock purchased in the open
market owned the Aries Master Fund II;
3. 316,301 shares of Common Stock issuable upon conversion of 684 shares of
Series C Convertible Preferred Stock; Warrants to purchase 104,229 shares
of Common Stock; and 332,229 shares of Common Stock purchased in the open
market owned Aries Domestic Fund, L.P.; and
4. 24,509 shares of Common Stock issuable upon conversion of 53 shares of
Series C Convertible Preferred Stock; Warrants to purchase 8,076 shares of
Common Stock; and 70,887 shares of Common Stock purchased in the open
market owned Aries Domestic Fund II, L.P.
Page 3 of 3
